ActiveSpans 6 functions & 3 industries
Updated

Healthcare Winners and Wallflowers: ResMed Shines as Select Medical and Biogen Stumble

Healthcare investors are rewarding efficient earners and punishing growth that doesn’t convert to cash.

What is this trend?

Capital-efficient healthcare businesses with durable margins and recurring earnings are gaining favor as investors discount revenue growth that fails to produce strong returns.

  • Profitability now matters more than headline sales growth.
  • Recurring revenue, margin discipline, and cash conversion are the new quality signals.
  • High debt and weak capital returns leave laggards exposed to harsher valuation resets.
  • Operational execution is separating resilient compounders from one-quarter wonders.
  • The bar is rising for funding innovation, buybacks, and weathering sector volatility.

What’s the latest?

Despite headline-grabbing gains, Garrett’s sluggish long-term growth and razor-thin margins cast doubt on the sustainability of its financial turnaround.

Garrett Motion Rockets on Q1 Beat—But Analysts Pump the Brakes on Long-Term Hopes

How it developed earlier updates

  1. Healthcare’s playing field is splitting: ResMed surges ahead with strong growth and margin gains, while Select Medical, Biogen, and others stumble under debt, shrinking profits, and skeptical investor

    Healthcare Winners and Wallflowers: ResMed Shines as Select Medical and Biogen Stumble

  2. Healthcare giants are sacrificing revenue for short-term earnings gains, but rising costs and poor capital efficiency threaten the sector’s long-term sustainability.

    Healthcare Stocks Under the Microscope: Investors Sour as Profits Fade, AI Picks Winners

  3. Despite beating revenue forecasts, medical device leaders face investor backlash as profit outlooks shrink and market headwinds intensify.

    Medical Device Giants Beat Expectations, But Wall Street Yawns Amid Guidance Gloom

  4. Catapult’s surging margins and debt-free balance sheet signal a new era of scalable growth, with management targeting nearly 50% EBITDA growth in FY27.

    Catapult Sports Rockets Higher as Brokers Race to Lift Targets After Record-Breaking FY26

  5. Despite recent stock weakness, Intuitive Surgical’s rapid revenue and EPS growth, hefty cash reserves, and historically discounted valuation underscore its resilience and strategic edge in MedTech.

    Intuitive Surgical Shines Beneath Sector Gloom—But Investors Eye Greener AI Pastures

  6. Brady’s revenue surge was matched by margin gains from disciplined cost controls and high-demand product launches, setting a new benchmark for sustainable profitability.

    Brady Blazes Past Peers: Q1 Surge Sparks Stock Rally and Upbeat Outlook in Security Sector

  7. Sustained revenue gains and rising EPS reveal which companies are turning demand into lasting, efficient growth while weaker peers risk falling behind.

    Cash Flow Kings: How Growth, AI, and Smart Capital Moves Are Separating Market Winners from Wannabes

  8. Investors are punishing medical device stocks with strong sales but weak earnings, rewarding only those who deliver on profit and guidance.

    ICU Medical Defies Sector Slump as Investors Shun Revenue-Only Wins in Medical Devices Shakeup

  9. Earnings season exposed a stark split: some vertical software firms soared on consistent execution while others slumped despite headline growth, as market sentiment trumped fundamentals.

    Revenue Beats, Stock Retreats: Vertical Software's Growth Paradox Deepens

  10. SoFi and peers like DoorDash and Coinbase are translating rapid revenue gains into surging profits, while Hope Bancorp’s weak earnings highlight the pitfalls of sluggish execution.

    SoFi's Cash Power Sparks Investor Debate: Growth Darling or Overhyped Outlier?

Where this is playing out

Functions

Industries

Related trends

Stay ahead of what’s changing

Get the weekly brief and deep-dive reporting in your inbox.